By Paul A. Bartlett, Michael Entzeroth
ISBN-10: 0854048421
ISBN-13: 9780854048427
Conceptual and technological advances in chemistry and biology have remodeled the drug discovery technique. Evolutionary strain one of the various medical and engineering disciplines that give a contribution to the identity of biologically lively compounds has ended in synergistic advancements at each step within the procedure. Exploiting Chemical range for Drug Discovery encompasses the numerous parts of this modification and provides the present state of the art of this severe endeavour. From the theoretical and operational concerns in producing a suite of compounds to monitor, to the layout and implementation of high-capacity and top of the range assays, this e-book presents a accomplished assessment of recent techniques to guide id.
Read or Download Exploiting Chemical Diversity for Drug Discovery (Biomolecular Sciences Series) (RSC Biomolecular Sciences) PDF
Similar chemistry books
The articles within the e-book deal with circulation instability and transition beginning with classical fabric handled in an cutting edge and rigorous manner, a few more recent actual mechanisms defined for the 1st time and at last with the very advanced subject of bombustion and two-phase circulate instabilities.
Physikalische Chemie wird von vielen Studierenden als schwer und trocken empfunden. Dieses Lehrbuch nach völlig neuem Konzept, das die Darstellung deutlich klarer werden lässt, zeigt, dass das nicht stimmen muss. Anschaulich und leicht verständlich gelingt mit diesem Buch der Einstieg in ein spannendes Gebiet der Chemie.
- Cephalosporins and Penicillins. Chemistry and Biology
- A Review of the literature published between September 1974 and August 1975
- One and Two Dimensional NMR Spectroscopy
- Modern Aspects of Electrochemistry №31
Extra info for Exploiting Chemical Diversity for Drug Discovery (Biomolecular Sciences Series) (RSC Biomolecular Sciences)
Sample text
C. A. Cawthorne, D. M. A. Smith and P. Thurlby, Biorg. Med. Chem. , 1994, 4, 1181–1184. X. Li, C. H. Warrington and M. Ladlow, Org. Biomol. , 2003, 1, 4392–4395. C. A. P. T. Duff, D. M. A. A. L. Thurlby, J. Med. , 1994, 37, 3977–3985. N. V. A. Procopiou, Org. , 2002, 4, 3793–3796. N. V. Ley, B. A. Procopiou, J. Chem. , Perkin Trans. 1, 2002, 2237–2242. T. I. R. A. A. Humbles, M. J. Vardey, Eur. J. , 1994, 251, 127–135. I. Storer, T. S. S. R. V. Ley, Chem. Eur. , 2004, 10, 2529–2547. C. Nicolaou, N.
Chem. , 1999, 121, 2965–2973. 105. D. H. Warrington and M. Ladlow, J. Comb. , 2004, 6, 584–595. 106. D. Jönsson and M. Ladlow, Unpublished results. 1 Typically, and perhaps a little simplified, if the focus used to be on pushing a small number of rationally designed drugs through the not always easily understood maze of preclinical and clinical studies, there is today a clear trend and willingness to improve the chances of presenting a successful drug by one of the simplest methods available: increasing the number of synthesized compounds.
1997, 40, 1347–1365. 96. C. M. P. Ferro, T. P. W. E. J. Capetola, J. Pharm. Exp. , 1994, 271, 1399–1408. 97. T. Kirchner, B. C. Y. M. Ritchie, Prostaglandins, Leukotrienes, and Essential Fatty Acids, 1997, 56, 417–423. 98. P. Hodge, Curr. Opin. Chem. , 2003, 7, 362–373. 99. R. Harrison and P. Hodge, J. Chem. , Perkin Trans. 1, 1976, 2252–2254. 100. A. Kirschning, C. Altwicker, G. Drager, J. Harders, N. Hoffmann, U. Hoffmann, H. Schonfeld, W. Solodenko and U. Kunz, Angew. Chem. Int. , 2001, 40, 3995–3998.
Exploiting Chemical Diversity for Drug Discovery (Biomolecular Sciences Series) (RSC Biomolecular Sciences) by Paul A. Bartlett, Michael Entzeroth
by Jason
4.2